Apellis Pharmaceuticals (APLS) News Today $24.37 +0.04 (+0.16%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$23.70 -0.68 (-2.77%) As of 08/8/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook4 hours ago | theglobeandmail.comING Groep NV Takes $4.03 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)August 7 at 5:57 AM | marketbeat.comBrokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $37.78August 6 at 3:13 AM | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysAugust 5, 2025 | marketbeat.comJ. Safra Sarasin Holding AG Decreases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)August 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)August 5, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00August 5, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceAugust 4, 2025 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $19.00 Price Target at Royal Bank Of CanadaAugust 4, 2025 | americanbankingnews.comWhat is Wedbush's Estimate for APLS Q3 Earnings?August 4, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Announces Earnings ResultsAugust 3, 2025 | marketbeat.comEnvestnet Asset Management Inc. Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)August 3, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Rating Increased to Hold at Wall Street ZenAugust 3, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 3, 2025 | marketbeat.comApellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price TargetAugust 2, 2025 | msn.comRoyal Bank Of Canada Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) StockAugust 2, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $40.00 Price Target at Cantor FitzgeraldAugust 2, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $50.00 Price Target at Raymond James FinancialAugust 2, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call TranscriptAugust 2, 2025 | seekingalpha.comApellis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 2, 2025 | seekingalpha.comApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up Following Earnings BeatAugust 2, 2025 | americanbankingnews.comApellis Pharmaceuticals: The Picture Becomes ClearerAugust 1, 2025 | seekingalpha.comApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up After Earnings BeatAugust 1, 2025 | marketbeat.comWilliam Blair Issues Positive Outlook for APLS EarningsAugust 1, 2025 | marketbeat.comWilliam Blair Brokers Raise Earnings Estimates for APLSAugust 1, 2025 | americanbankingnews.comApellis’ EMPAVELI Approved by FDA for Rare Kidney DiseasesJuly 31, 2025 | msn.comApellis Pharmaceuticals Reports Second Quarter 2025 Financial ResultsJuly 31, 2025 | globenewswire.comWilliam Blair Issues Optimistic Forecast for APLS EarningsJuly 31, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $46.00 at CitigroupJuly 31, 2025 | americanbankingnews.comWhat To Expect From Apellis Pharmaceuticals Inc (APLS) Q2 2025 EarningsJuly 30, 2025 | finance.yahoo.comCitigroup Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceJuly 30, 2025 | marketbeat.comApellis wins FDA label expansion for Empaveli in rare kidney disordersJuly 29, 2025 | msn.comApellis stock soars after FDA approves first C3G treatmentJuly 29, 2025 | za.investing.comApellis shares jump 12% following FDA approval of first-ever C3G treatmentJuly 29, 2025 | msn.comApellis Pharmaceuticals trading halted, news pendingJuly 28, 2025 | msn.comFDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and OlderJuly 28, 2025 | globenewswire.comY Intercept Hong Kong Ltd Buys Shares of 29,577 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)July 27, 2025 | marketbeat.comVictory Capital Management Inc. Has $4.71 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)July 27, 2025 | marketbeat.comApellis Pharmaceuticals (APLS) to Release Earnings on ThursdayJuly 26, 2025 | marketbeat.comApellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial ResultsJuly 24, 2025 | globenewswire.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,000 SharesJuly 19, 2025 | marketbeat.comCedric Francois Sells 19,725 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJuly 19, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $97,750.00 in StockJuly 19, 2025 | insidertrades.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Decreased by Jennison Associates LLCJuly 19, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Cwm LLCJuly 19, 2025 | marketbeat.com3APLS : Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives...July 18, 2025 | benzinga.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $50.00July 18, 2025 | marketbeat.comCedric Francois Sells 1,900 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJuly 17, 2025 | insidertrades.comWedbush Research Analysts Boost Earnings Estimates for APLSJuly 17, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $38,171.00 in StockJuly 16, 2025 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.750.38▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼259▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News MRNA News ASND News VTRS News BBIO News VRNA News BPMC News ROIV News GRFS News LEGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts